Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10134614 | 0.90 | MGLL (0.38) | ALDH1A1KDM4EHPGDHSD17B10MGLL | |
| SCHEMBL10134603 | 0.87 | MGLL (0.36) | ALDH1A1KDM4EHPGDPOLBMGLL | |
| SCHEMBL6744910 | 0.87 | MEN1 (0.37) | ALDH1A1KDM4EHPGDPOLBMGLL | |
| SCHEMBL13265179 | 0.82 | ALDH1A1 (0.40) | ALDH1A1KDM4EHPGDHSD17B10POLB | |
| SCHEMBL6742571 | 0.79 | CYP1A2 (0.41) | ALDH1A1KDM4EHPGDMGLLTDP1 | |
| SCHEMBL6744725 | 0.79 | KDM4E (0.37) | ALDH1A1KDM4EPOLBMGLLTDP1 | |
| SCHEMBL4610155 | 0.78 | ALDH1A1 (0.46) | ALDH1A1TDP1GLA | |
| SCHEMBL4610163 | 0.78 | ALDH1A1 (0.46) | ALDH1A1TDP1GLA | |
| SCHEMBL6744920 | 0.77 | KDM4E (0.32) | ALDH1A1KDM4EHPGDHSD17B10MGLL | |
| SCHEMBL10134601 | 0.77 | CYP4F2 (0.37) | ALDH1A1MGLLTDP1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173631-B2 | Cyclic amine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173631-B2 | Cyclic amine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | RYR2, CASR, RYR1 | ALDH1A1 2584/4885KDM4E 3243/4885HPGD 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.